ProfileGDS4814 / ILMN_1809208
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 73% 69% 71% 73% 70% 70% 71% 71% 74% 72% 73% 74% 72% 70% 72% 72% 69% 71% 78% 74% 72% 74% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)84.036373
GSM780708Untreated after 4 days (C2_1)69.198869
GSM780709Untreated after 4 days (C3_1)75.43371
GSM780719Untreated after 4 days (C1_2)88.067473
GSM780720Untreated after 4 days (C2_2)74.773170
GSM780721Untreated after 4 days (C3_2)72.930970
GSM780710Trastuzumab treated after 4 days (T1_1)76.304371
GSM780711Trastuzumab treated after 4 days (T2_1)76.545671
GSM780712Trastuzumab treated after 4 days (T3_1)89.659974
GSM780722Trastuzumab treated after 4 days (T1_2)80.767772
GSM780723Trastuzumab treated after 4 days (T2_2)85.554673
GSM780724Trastuzumab treated after 4 days (T3_2)91.712474
GSM780713Pertuzumab treated after 4 days (P1_1)81.517772
GSM780714Pertuzumab treated after 4 days (P2_1)73.006770
GSM780715Pertuzumab treated after 4 days (P3_1)80.580972
GSM780725Pertuzumab treated after 4 days (P1_2)79.604872
GSM780726Pertuzumab treated after 4 days (P2_2)70.994169
GSM780727Pertuzumab treated after 4 days (P3_2)76.12971
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)121.00678
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)94.503674
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)83.400472
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)91.662274
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)86.156373